LAUSR

Simple Summary Endocrine tumors often cause hormonal imbalances and sometimes hormone syndrome. Generally, the prognosis of patients with metastatic endocrine malignancies is poor due to recurrence and treatment failure. Aberrant expression of m6A may disrupt the development and occurrence of malignancies. We provide a theoretical foundation for the development of new diagnostic markers and therapeutic techniques based on m6A alteration and regulators in endocrine cancers. Abstract With the development of RNA modification research, N6-methyladenosine (m6A) is regarded as one of the most important internal epigenetic modifications of eukaryotic mRNA. It is also regulated by methylase, demethylase, and protein preferentially recognizing the m6A modification. This dynamic and reversible post-transcriptional RNA alteration has steadily become the focus of cancer research. It can increase tumor stem cell self-renewal and cell proliferation. The m6A-modified genes may be the primary focus for cancer breakthroughs. Although some endocrine cancers are rare, they may have a high mortality rate. As a result, it is critical to recognize the significance of endocrine cancers and identify new therapeutic targets that will aid in improving disease treatment and prognosis. We summarized the latest experimental progress in the m6A modification in endocrine cancers and proposed the m6A alteration as a potential diagnostic marker for endocrine malignancies.